Elabela and Apelin actions in healthy and pathological pregnancies
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Pregnancy is a dynamic and precisely organized process during which one or more baby develops. Embryonic development relies on the formation of the placenta, allowing nutrient and oxygen exchange between the mother and the fetus. Dysfunction of placental formation lead to pregnancy disorders such as preeclampsia (PE) with serious deleterious consequences for fetal and maternal health. Identifying factors involved in fetoplacental homeostasis could inform better diagnostic and therapeutic strategies for these pathological pregnancies. Here, we summarize actions of elabela, apelin and their common receptor APJ in the fetoplacental unit. Studies indicate that elabela is crucial for embryo cardiovascular system formation and early placental development, while apelin acts in mid/late gestation to modulate fetal angiogenesis and energy homeostasis. Most of these findings, drawn from animal models, indicate a key role of elabela/apelin-APJ system in the fetoplacental unit. This review also provides an overview of clinical studies investigating elabela/apelin-APJ system in pathological complicated pregnancies such as PE and gestational diabetes mellitus (GDM). While elabela-deficient mice display all the features of PE, current clinical studies show no difference in circulating elabela levels between PE and control patients which does not support a role in PE development. Conversely, apelin levels are increased during PE, but the use of apelin as an early PE marker remains to be fully investigated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Circulating angiogenic factors and the risk of preeclampsia
Levine, R. J., Maynard, S. E., Qian, C., Lim, K.-H., England, L. J., Yu, K. F., Schisterman, E. F., Thadhani, R., Sachs, B. P., Epstein, F. H., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031884 · Cited by 3,720
Soluble endoglin contributes to the pathogenesis of preeclampsia
Venkatesha, S., Toporsian, M., Lam, C., Hanai, J.-I., Mammoto, T., Kim, Y. M., Bdolah, Y., Lim, K.-H., Yuan, H.-T., Libermann, T. A., et al. (2006) · Nature Medicine · doi:10.1038/nm1429 · Cited by 1,855
Apelin, a Newly Identified Adipokine Up-Regulated by Insulin and Obesity
Boucher, J., Masri, B., Daviaud, D., Gesta, S., Guigné, C., Mazzucotelli, A., Castan-Laurell, I., Tack, I., Knibiehler, B., Carpéné, C., et al. (2005) · Endocrinology · doi:10.1210/en.2004-1427 · Cited by 910
Adipokines in gestational diabetes
Fasshauer, M., Blüher, M., & Stumvoll, M. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70176-1 · Cited by 230
Cited by
Pathogenesis of Preeclampsia and Therapeutic Approaches Targeting the Placenta
Jena, M. K., Sharma, N. R., Petitt, M., Maulik, D., & Nayak, N. R. (2020) · Biomolecules · doi:10.3390/biom10060953 · Cited by 261
Targeting the apelin system for the treatment of cardiovascular diseases
Chapman, F. A., Maguire, J. J., Newby, D. E., Davenport, A. P., & Dhaun, N. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvad171 · Cited by 104
Son, J. S., Zhao, L., Chen, Y., Chen, K., Chae, S. A., de Avila, J. M., Wang, H., Zhu, M.-J., Jiang, Z., & Du, M. (2020) · Science Advances · doi:10.1126/sciadv.aaz0359 · Cited by 101
“These developing vascular endothelial cells are major sources of apelin secretion (17).”
BackgroundSzlapinski, S. K., & Hill, D. J. (2020) · Current Vascular Pharmacology · doi:10.2174/1570161118666200320111209 · Cited by 56
Metadata
- Authors
- Eberlé, D., Marousez, L., Hanssens, S., Knauf, C., Breton, C., Deruelle, P., & Lesage, J.
- Venue
- Cytokine & Growth Factor Reviews
- Publisher
- Elsevier BV
- Published
- 2019-04
- Volume
- 46
- Pages
- 45-53
- ISSN
- 1359-6101 (ISSN-L)
- OpenAlex
- W2922182130
- Cited by
- 50
- References
- 4
- FWCI
- 1.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.